Pros and cons of using biomarkers versus clinical decisions in start and stop decisions for antibiotics in the critical care setting.
about
Antimicrobial Stewardship: How the Microbiology Laboratory Can Right the ShipImproving the Recognition of, and Response to In-Hospital Sepsis.[Procalcitonin as a tool for the assessment of successful therapy of severe sepsis : An analysis using clinical routine data].Metabolites in Blood for Prediction of Bacteremic Sepsis in the Emergency Room.Shorter Duration of Post-Operative Antibiotics for Cecal Ligation and Puncture Does Not Increase Inflammation or MortalityA Broad-Spectrum Infection Diagnostic that Detects Pathogen-Associated Molecular Patterns (PAMPs) in Whole BloodProcalcitonin-guided antibiotic treatment in critically ill patients.Calprotectin as a Biomarker for Melioidosis Disease Progression and Management.The Intensive Care Medicine research agenda on critically ill oncology and hematology patients.A Pragmatic Biomarker-Driven Algorithm to Guide Antibiotic Use in the Pediatric Intensive Care Unit: The Optimizing Antibiotic Strategies in Sepsis (OASIS) Study.Serum activin-A as a predictive and prognostic marker in critically ill patients with sepsis.PIRATE project: point-of-care, informatics-based randomised controlled trial for decreasing overuse of antibiotic therapy in Gram-negative bacteraemia.Use of C-Reactive Protein as a Diagnostic Tool for Early Detection of Bacterial Infection After Liver Transplantation.Focus on infection and sepsis in intensive care patients.Evaluation of the use of novel biomarkers to augment antimicrobial stewardship program activities.
P2860
Q28068503-A6CA0A22-E52B-4F8E-921C-87A3B8C32BFCQ30250272-F8CEA847-ABCC-4341-A384-463386A8E329Q31112286-555F94A7-B64F-4923-87FC-BCED46D6B147Q35901678-0368398F-295A-455C-8627-EFAC71B99E78Q36144916-CEEECAAF-0F5F-4E9A-B8C8-D8F3461CB480Q37149965-108478F5-5BD2-487B-B092-7F36981CE0AFQ38860643-C3CF5F84-594A-4C4C-8499-833D87B1DA36Q39295421-9C0E8FB8-BB92-4F4E-90E7-91F8043CB641Q39446746-AED0A9B1-3BD2-43B2-87BF-28C3DBECBE30Q39793018-B78784FC-154F-4FCB-80BF-934F130F8ADDQ39926432-05A9AF0B-2FF9-4F8D-A55D-F34FABE11752Q40122073-A1ED6550-BDFD-4AFA-BCB5-812E95154CBEQ40459074-A8BF9BAB-F04D-47CD-B93A-3E118F0B7919Q40797788-5779555A-1689-47A6-9156-4ACD5E8A6B6BQ47289498-C82C0F34-2B4B-4443-BB3D-ED66EF249375
P2860
Pros and cons of using biomarkers versus clinical decisions in start and stop decisions for antibiotics in the critical care setting.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Pros and cons of using biomark ...... in the critical care setting.
@en
type
label
Pros and cons of using biomark ...... in the critical care setting.
@en
prefLabel
Pros and cons of using biomark ...... in the critical care setting.
@en
P2860
P1476
Pros and cons of using biomark ...... in the critical care setting.
@en
P2093
Werner C Albrich
P2860
P2888
P304
P356
10.1007/S00134-015-3978-8
P577
2015-07-21T00:00:00Z